Quick Links

Home
Registration
Registration Program (PDF)
Livestream
Meeting Information
Education Information
About ACAAI
 
Interested in becoming an ACAAI member? Learn more about the benefits of membership and find your place in the College.

LATE-BREAKING ABSTRACTS - Submission Guidance

 

ACAAI 2026 ANNUAL SCIENTIFIC MEETING
Podium to Practice© - Building Bridges for the Future
November 12 - 16, 2026
Phoenix, AZ
 

Submission Period: September 1 - October 6, 2026

The College invites you to submit a late-breaking abstract for the ACAAI 2026 Annual Scientific Meeting, November 12 - 16, 2026, in Phoenix, AZ.

Late-Breaking abstracts must include innovative research results that were not available by the regular abstract deadline. Due to the nature of these abstracts, there will be a VERY LIMITED number of abstracts accepted. Late-breaking abstracts must contain primary data from groundbreaking laboratory studies or from novel or large clinical trials.

IMPORTANT SUBMISSION DETAILS

  • One Presenting Author for each accepted abstract must register for and attend the ACAAI 2026 Annual Scientific Meeting in Phoenix, AZ. 
  • A Presenting Author must be identified by the submission deadline date for the abstract to be considered for acceptance.
  • Abstracts may be submitted by fellows, members and non-members of the College.
  • ACAAI only accepts original abstracts. Abstracts previously accepted and/or published by other organizations should not be submitted. If an abstract submitted to ACAAI Annual Meeting is accepted for programming and/or publication by another organization prior to its acceptance by ACAAI, it must be withdrawn from consideration for the ACAAI Annual Meeting.
  • Abstracts reporting results of quality improvement work will be accepted. See "Organization of Abstract Body" below for submission guidance.
  • ACAAI recognizes the use of generative artificial intelligence (AI) as a powerful tool for educators and researchers and encourages its responsible and ethical use. If any form of generative AI is utilized for this abstract submission, it must be clearly acknowledged in the appropriate section(s) within the abstract content. It is expected that authors will review any AI-generated copy. AI cannot be used to generate figures or images. Presenting inaccurate AI-generated information or failing to acknowledge AI-generated information will result in disqualification.
  • Accepted abstracts will be published in the November online supplement of the Annals of Allergy, Asthma & Immunology©.
  • The highest scoring, late-breaking abstracts will be considered for presentation during the in-person Oral Abstract sessions.
  • There is a $250 non-refundable fee for each abstract submission. Payment does not guarantee that the abstract will be accepted.
  • Abstracts must be submitted electronically via the online form, and they must be complete, including the author listing. ACAAI will not accept any changes after the October 6, 2026 - 5:00 pm (CT) submission deadline.

All accepted Abstracts will be published online as they appear within the ACAAI System as of the deadline date. No changes can be made to the abstract after the close of the submission period.

Late-breaking Abstract Submission Guidance

An unlimited number of Authors are allowed for late-breaking abstracts. 

Authorship. The College follows the ICMJE quidelines. The ICMJE recommends that authorship be based on the following 4 criteria:

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
NOTE: All correspondence regarding the abstract submission will be sent to the abstract submitter at the email address provided at time of submission. It is the responsibility of the submitter to ensure that all information is correct and approved by the participating authors.

SUBMITTER INFORMATION

As the Submitter, you will be the main contact person for the abstract, and as such, it will be your responsibility to make sure the other authors are informed of any communications from ACAAI regarding the abstract (including requests from the ACAAI Abstract Review Subcommittee for additional information, disposition and placement decision, missing disclosures, etc.). If you are unwilling or unable to function in this capacity, please designate someone else as the contact person.

It is the responsibility of the submitting author to ensure accuracy of content, spelling and author information, including listing order. Abstracts are directly exported from the submission database for publication.

Please review your submission carefully to make sure that all appropriate data is included and that all authors are listed and in the correct order. Absolutely no abstract changes will be accepted after the submission deadline of October 6, 2026, 5:00 pm (CT).

Commercial Bias. All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores or rejection. 

Abstract Withdrawal. If the Submitting Author wishes to withdraw his/her case from the Annual Meeting program, a written request (via email) must be submitted to maureenknight@acaai.org by October 6, 2026. 

CME Financial Disclosure
In accordance with the ACCME Standards for Commercial Support the American College of Allergy, Asthma & Immunology (ACAAI), as an accredited provider, must ensure all CME Planners, Speakers, Presenters, Authors involved in the development of CME content and/or presentation of content, disclose to the accredited provider ALL*financial relationship(s) with any ACCME-defined **ineligible company(ies) [see definition of ineligible company below].

**ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies

All authors must complete the online Disclosure of Financial Relationships by October 6, 2026 at 5:00 pm (CT) or their names will be pulled as an abstract author.

Disclosure of relevant financial relationships includes the name of the ineligible company and the relationship. 

REQUIRED INFORMATION FOR EACH AUTHOR:

  1. You must list your authors in the order in which they should appear in the abstract. Presenting Authors can appear anywhere within the list and must be designated as the Presenting Author. An unlimited number of authors may be included for late-breaking abstracts.  A Presenting Author who will register for the ACAAI 2026 Annual Meeting and appear in-person to present the abstract, must be identified by the deadline date for the abstract to be considered for acceptance.
  2. First Name, Middle Initial and Last Name
  3. Company/Institution Name
  4. City, State and Country (where employed)
  5. Author Email
  6. All authors listed on your abstract will receive an email with a link to complete their disclosure. Please make sure they respond; all authors listed on your abstract are REQUIRED to disclose and it will be your responsibility as the submitter to follow-up with the authors to make sure the disclosures have been submitted. They will continue to receive auto-reminders each time an abstract is revised or submitted until they have complied with the disclosure request.

ORGANIZATION OF ABSTRACT BODY

Title
There is a limit of 15 words. Use only standard alpha/numeric characters in your title. Do not use symbols. Capitalize the first letter of each word of the title. Do not use formatting tags in the title. The title will be formatted automatically by the system at the time of online production. Abbreviations must not be used in the title. The system does not monitor for Title character count. Check to ensure that you have not exceeded the character count limit. If the limit is exceeded, the system will automatically remove letters/words from the end in order to meet the 15 word limit.

Abstract Length
There is a limit of  250 words for the body of your abstract submission.

Abstract Body
The abstract  must contain the words “Introduction, Methods, Results, Conclusion” in the body to indicate the start of each new section. The abstract title and author information must not be included in the body of the abstract. Do not include references within the body of your abstract.

Introduction: A brief introduction indicating the reason for the study

Methods: A description of the methods used to evaluate the study (do not include laboratory techniques)

Results: Specific data necessary to evaluate the abstract (Statements such as “data will be discussed at the presentation” are grounds for refusal of the abstract)

Conclusion: A brief conclusion indicating the significance of the results in terms of what was originally designed. The results should occupy 1/2 to 2/3 of the abstract. DO NOT mention the institution where the work was performed in the body or title of the abstract.

Best Results. Best results are achieved by typing directly into the "body" area of the submission form.  If you are entering the copy directly onto the Abstract Form, you must use the “Symbols” icon to ensure your results are displayed accurately. Always verify that your information is correct prior to submitting by selecting "Print Preview."

Editorial Policies for Authors (ICMJE Guidance)
Reproduced Materials - When previously published figures or tables are used, the author must obtain written permission from the copyright holder (usually the publisher) to reproduce the material. An appropriate credit line and publication information should be included in the figure legend or table footnote. Letters of permission must accompany the manuscript at the time of submission.

Use of Figures. You may add one figure to your abstract, however, it is recommended that results be shown in narrative form, since figure formats may be compromised in publication. The figure must be submitted as a jpg file and cannot exceed 500kb.

Late-breaking Abstract Acceptance. If the abstract is accepted for presentation at the ACAAI 2026 Annual Meeting, the submitter will be notified via email in early to mid-October. Only the submitter will be notified of the abstract disposition. Please ensure that all contact information is accurate. The notification will include the scheduled date, time and location of the presentation.

Abstracts accepted for presentation will be grouped by topic, numbered and listed in the program and published in the online November issue of the Annals of Allergy, Asthma and Immunology® abstract supplement. The decision of the ACAAI Abstract Review Subcommittee regarding acceptance and presentation of abstracts is final.

Meeting Registration. All Presenting Authors must register for, and attend, the ACAAI 2026 Meeting in Phoenix and pay any applicable registration fees. Visit the ACAAI Annual Meeting website to Register.


 

Visit the Abstracts FAQ page for answers to frequently asked questions.

 

Back to Top